Mechanisms of chemotherapy resistance in ovarian cancer

被引：92
作者：
Ortiz, Mylena [1 ,2 ]
Wabel, Emma [1 ,2 ]
Mitchell, Kerry [1 ]
Horibata, Sachi [1 ,2 ]
机构：
[1] Michigan State Univ, Precis Hlth Program, 766 Serv Rd, E Lansing, MI 48824 USA
[2] Michigan State Univ, Coll Human Med, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA
来源：
CANCER DRUG RESISTANCE | 2022年 / 5卷 / 02期
关键词：
Drug resistance; ovarian cancer; cisplatin; carboplatin; paclitaxel; olaparib; niraparib; bevacizumab; CISPLATIN-RESISTANCE; MULTIDRUG-RESISTANCE; PLATINUM-RESISTANCE; DRUG-RESISTANCE; CARCINOMA; EXPRESSION; TRANSPORT; PACLITAXEL; INDUCTION; TUMORS;
D O I：
10.20517/cdr.2021.147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (olaparib and niraparib) and one vascular endothelial growth factor inhibitor (bevacizumab) as maintenance therapies for ovarian cancer. In this review, we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.
引用
收藏
页码：304 / 316
页数：13
相关论文
共 80 条
[1]   Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake [J].
Arjaans, Marlous ;
Munnink, Thijs H. Oude ;
Oosting, Sjoukje F. ;
van Scheltinga, Anton G. T. Terwisscha ;
Gietema, Jourik A. ;
Garbacik, Erik T. ;
Timmer-Bosscha, Hetty ;
Lub-de Hooge, Marjolijn N. ;
Schroder, Carolina P. ;
de Vries, Elisabeth G. E. .
CANCER RESEARCH, 2013, 73 (11) :3347-3355
[2]   Integrated genomic analyses of ovarian carcinoma [J].
Bell, D. ;
Berchuck, A. ;
Birrer, M. ;
Chien, J. ;
Cramer, D. W. ;
Dao, F. ;
Dhir, R. ;
DiSaia, P. ;
Gabra, H. ;
Glenn, P. ;
Godwin, A. K. ;
Gross, J. ;
Hartmann, L. ;
Huang, M. ;
Huntsman, D. G. ;
Iacocca, M. ;
Imielinski, M. ;
Kalloger, S. ;
Karlan, B. Y. ;
Levine, D. A. ;
Mills, G. B. ;
Morrison, C. ;
Mutch, D. ;
Olvera, N. ;
Orsulic, S. ;
Park, K. ;
Petrelli, N. ;
Rabeno, B. ;
Rader, J. S. ;
Sikic, B. I. ;
Smith-McCune, K. ;
Sood, A. K. ;
Bowtell, D. ;
Penny, R. ;
Testa, J. R. ;
Chang, K. ;
Dinh, H. H. ;
Drummond, J. A. ;
Fowler, G. ;
Gunaratne, P. ;
Hawes, A. C. ;
Kovar, C. L. ;
Lewis, L. R. ;
Morgan, M. B. ;
Newsham, I. F. ;
Santibanez, J. ;
Reid, J. G. ;
Trevino, L. R. ;
Wu, Y. -Q. ;
Wang, M. .
NATURE, 2011, 474 (7353) :609-615
[3]   Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types [J].
Ben-Hamo, Rotem ;
Zilberberg, Alona ;
Cohen, Helit ;
Bahar-Shany, Keren ;
Wachtel, Chaim ;
Korach, Jacob ;
Aviel-Ronen, Sarit ;
Barshack, Iris ;
Barash, Danny ;
Levanon, Keren ;
Efroni, Sol .
NPJ PRECISION ONCOLOGY, 2019, 3 (1)
[4]  
Brill E, IN VITRO CELL DEV B, V8
[5]   VEGF as a key mediator of angiogenesis in cancer [J].
Carmeliet, P .
ONCOLOGY, 2005, 69 :4-10
[6]   Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer [J].
Colombo, Pierre-Emmanuel ;
Fabbro, Michel ;
Theillet, Charles ;
Bibeau, Frederic ;
Rouanet, Philippe ;
Ray-Coquard, Isabelle .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 89 (02) :207-216
[7]   Platinum Resistance in Ovarian Cancer: Role of DNA Repair [J].
Damia, Giovanna ;
Broggini, Massimo .
CANCERS, 2019, 11 (01)
[8]   Cisplatin in cancer therapy: Molecular mechanisms of action [J].
Dasari, Shaloam ;
Tchounwou, Paul Bernard .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 740 :364-378
[9]   High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer [J].
Du, Pei ;
Wang, Yifeng ;
Chen, Liquan ;
Gan, Yaping ;
Wu, Qinian .
ONCOLOGY LETTERS, 2016, 12 (02) :857-862
[10]   EphB4 controls blood vascular morphogenesis during postnatal angiogenesis [J].
Erber, R ;
Eichelsbacher, U ;
Powajbo, V ;
Korn, T ;
Djonov, V ;
Lin, JH ;
Hammes, HP ;
Grobholz, R ;
Ullrich, A ;
Vajkoczy, P .
EMBO JOURNAL, 2006, 25 (03) :628-641
12345678